Update on Eosinophil Interaction with Mast Cells: The Allergic Effector Unit

Citation:

Roopesh Singh Gangwar, Hadas Pahima, Pier Giorgio Puzzovio, and Francesca Levi-Schaffer. 2021. “Update on Eosinophil Interaction with Mast Cells: The Allergic Effector Unit.” Methods in Molecular Biology, 2241, Pp. 221–242.

Abstract:

Mast cells and eosinophils are the key effector cells of allergy [1]. In general, allergic reactions are composed of two phases, namely an early phase and a late phase, and after that resolution occurs. If the allergic reactions fail to resolve after the late phase, allergic inflammation (AI) can evolve into a chronic phase mainly involving mast cells and eosinophils that abundantly coexist in the inflamed tissue in the late and chronic phases and cross-talk in a bidirectional manner. We defined these bidirectional interactions between MCs and Eos, as the “allergic effector unit.” This cross talk is mediated by both physical cell-cell contacts through cell surface receptors such as CD48, 2B4, and respective ligands and through released mediators such as various specific granular mediators, arachidonic acid metabolites, cytokines, and chemokines [2, 3]. The allergic effector unit can be studied in vitro in a customized co-culture system using mast cells and eosinophils derived from either mouse or human sources.